A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

PURPOSE: To determine the dose limiting toxicities (DLTs), maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of veliparib in combination with weekly topotecan in patients with solid tumors. Correlative studies were included to assess the impact of topotecan and veliparib on poly(ADP-r...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Wahner Hendrickson, Andrea E., Menefee, Michael E., Hartmann, Lynn C., Long, Harry J., Northfelt, Donald W., Reid, Joel M., Boakye-Agyeman, Felix, Kayode, Olumide, Flatten, Karen S., Harrell, Maria I., Swisher, Elizabeth M., Poirer, Guy G., Satele, Daniel, Allred, Jake, Lensing, Janet L., Chen, Alice, Ji, Jiuping, Zang, Yiping, Erlichman, Charles, Haluska, Paul, Kaufmann, Scott H.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7580251/
https://ncbi.nlm.nih.gov/pubmed/29138343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1590
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky